Zoledronic Acid Every 12 Weeks Noninferior in Bone Metastases

Share this content:
Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events among patients with bone metastases.
Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events among patients with bone metastases.

(HealthDay News) -- Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, according to a study published in the Journal of the American Medical Association.

Andrew L. Himelstein, M.D., from the Helen F. Graham Cancer Center & Research Institute in Newark, Del., and colleagues randomized 1,822 patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with at least one site of bone involvement to receive zoledronic acid administered intravenously every four weeks or every 12 weeks (911 each) for two years. Of the patients, 795 completed the study at two years.

The researchers found that 29.5 and 28.6 percent of patients in the zoledronic acid four-week and 12-week groups, respectively, experienced at least one skeletal-related event within two years of randomization (risk difference, −0.3 percent; P < 0.001 for noninferiority).

The proportions of skeletal-related events did not differ between the groups for patients with breast cancer, prostate cancer, or multiple myeloma. Between the treatment groups there was no significant difference in pain scores, performance status scores, incidence of jaw osteonecrosis, and kidney dysfunction. Both groups had numerically identical skeletal morbidity rates, but greater turnover was seen among patients who received zoledronic acid every 12 weeks.

RELATED: Denosumab Non-inferior to Zoledronic Acid for Delaying Time to Skeletal-related Event

"This longer interval may be an acceptable treatment option," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Reference

  1. Himelsteon AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastasis. JAMA. 2017 Jan 3. doi:10.1001/jama.2016.19425. [Epub ahead of print.]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters